Finch Therapeutics Group Stock Analysis
FNCH Stock | USD 2.60 0.29 10.03% |
Finch Therapeutics Group is undervalued with Real Value of 14.37 and Target Price of 50.0. The main objective of Finch Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Finch Therapeutics Group is worth, separate from its market price. There are two main types of Finch Therapeutics' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Finch Therapeutics' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Finch Therapeutics' stock to identify patterns and trends that may indicate its future price movements.
The Finch Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Finch Therapeutics is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Finch Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Finch Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
Finch |
Finch Stock Analysis Notes
About 53.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.18. Some equities with similar Price to Book (P/B) outperform the market in the long run. Finch Therapeutics recorded a loss per share of 61.48. The entity had not issued any dividends in recent years. The firm had 1:30 split on the 12th of June 2023. Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts. Finch Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 189 people. To learn more about Finch Therapeutics Group call Mark Smith at 617 229 6499 or check out https://www.finchtherapeutics.com.Finch Therapeutics Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Finch Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Finch Therapeutics Group or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Finch Therapeutics generated a negative expected return over the last 90 days | |
Finch Therapeutics has high historical volatility and very poor performance | |
Finch Therapeutics has a very high chance of going through financial distress in the upcoming years | |
The company reported the previous year's revenue of 107 K. Net Loss for the year was (74.75 M) with loss before overhead, payroll, taxes, and interest of (57.03 M). | |
Finch Therapeutics Group currently holds about 104.67 M in cash with (31.5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.19. | |
Finch Therapeutics has a poor financial position based on the latest SEC disclosures | |
Roughly 53.0% of the company shares are held by company insiders | |
Latest headline from investorplace.com: FNCH Stock Earnings Finch Therapeutics Gr Reported Results for Q4 2023 |
Finch Therapeutics Upcoming and Recent Events
Earnings reports are used by Finch Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Finch Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
28th of March 2024 Upcoming Quarterly Report | View | |
8th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
28th of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Finch Largest EPS Surprises
Earnings surprises can significantly impact Finch Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2021-08-10 | 2021-06-30 | -0.28 | -0.32 | -0.04 | 14 | ||
2022-08-11 | 2022-06-30 | -0.41 | -0.48 | -0.07 | 17 | ||
2022-03-31 | 2021-12-31 | -0.32 | -0.4 | -0.08 | 25 |
Finch Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Finch Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Finch Therapeutics Group backward and forwards among themselves. Finch Therapeutics' institutional investor refers to the entity that pools money to purchase Finch Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Royal Bank Of Canada | 2023-12-31 | 27.0 | Bank Of America Corp | 2023-12-31 | 12.0 | Wells Fargo & Co | 2023-12-31 | 6.0 | Moisand Fitzgerald Tamayo, Llc | 2023-12-31 | 3.0 | Cutler Group Lp | 2023-12-31 | 3.0 | Ubs Group Ag | 2023-12-31 | 2.0 | Msd Partners, L.p. | 2023-12-31 | 0.0 | Lake Street Advisors Group, Llc | 2023-12-31 | 0.0 | Ancora Advisors Llc | 2023-12-31 | 0.0 | Baupost Group Llc | 2023-12-31 | 67.3 K | Susquehanna International Group, Llp | 2023-12-31 | 59 K |
Finch Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.18 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Finch Therapeutics's market, we take the total number of its shares issued and multiply it by Finch Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Finch Profitablity
Finch Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Finch Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Finch Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Finch Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Finch Therapeutics' profitability requires more research than a typical breakdown of Finch Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last Reported | Projected for 2024 | ||
Return On Capital Employed | (0.51) | (0.53) | |
Return On Assets | (1.05) | (1.11) | |
Return On Equity | (3.27) | (3.10) |
Management Efficiency
Finch Therapeutics has return on total asset (ROA) of (0.1947) % which means that it has lost $0.1947 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2606) %, meaning that it created substantial loss on money invested by shareholders. Finch Therapeutics' management efficiency ratios could be used to measure how well Finch Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Capital Employed is estimated to decrease to -0.53. The current Return On Assets is estimated to decrease to -1.11. As of now, Finch Therapeutics' Net Tangible Assets are increasing as compared to previous years. The Finch Therapeutics' current Non Current Assets Total is estimated to increase to about 52.4 M, while Total Assets are projected to decrease to under 52.6 M.Last Reported | Projected for 2024 | ||
Price Book Value Ratio | 0.25 | 0.27 | |
Enterprise Value Multiple | (0.33) | (0.35) | |
Price Fair Value | 0.25 | 0.27 |
The analysis of Finch Therapeutics' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Finch Therapeutics' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Finch Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 0.443 |
Technical Drivers
As of the 29th of March, Finch Therapeutics shows the Mean Deviation of 4.23, standard deviation of 6.88, and Variance of 47.27. Finch Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down thirteen technical drivers for Finch Therapeutics Group, which can be compared to its rivals. Please confirm Finch Therapeutics variance, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if Finch Therapeutics is priced favorably, providing market reflects its regular price of 2.6 per share. Please also check Finch Therapeutics Group jensen alpha, which is currently at (0.38) to verify the company can sustain itself at a future point.Finch Therapeutics Price Movement Analysis
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Finch Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Finch Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Finch Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Finch Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Finch Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Finch Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Smisek Jeffery A over three months ago Sale by Smisek Jeffery A of 1470 shares of Finch Therapeutics | ||
Blischak Matthew P over six months ago Acquisition by Blischak Matthew P of 962899 shares of Finch Therapeutics subject to Rule 16b-3 | ||
Blaustein Marc over a year ago Sale by Blaustein Marc of 4619 shares of Finch Therapeutics |
Finch Therapeutics Predictive Daily Indicators
Finch Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Finch Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Accumulation Distribution | 2105.68 | |||
Daily Balance Of Power | (0.76) | |||
Rate Of Daily Change | 0.9 | |||
Day Median Price | 2.67 | |||
Day Typical Price | 2.65 | |||
Price Action Indicator | (0.21) | |||
Period Momentum Indicator | (0.29) |
Finch Therapeutics Corporate Filings
10K | 25th of March 2024 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
8K | 23rd of February 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 13th of December 2023 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F4 | 27th of November 2023 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 17th of November 2023 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 8th of November 2023 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
11th of August 2023 Other Reports | ViewVerify | |
10Q | 10th of August 2023 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Finch Therapeutics Forecast Models
Finch Therapeutics' time-series forecasting models are one of many Finch Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Finch Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Finch Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Finch Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Finch shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Finch Therapeutics. By using and applying Finch Stock analysis, traders can create a robust methodology for identifying Finch entry and exit points for their positions.
Last Reported | Projected for 2024 | ||
Pretax Profit Margin | (730.98) | (694.43) | |
Operating Profit Margin | (317.78) | (301.89) | |
Net Loss | (698.64) | (663.70) | |
Gross Profit Margin | (13.21) | (12.55) |
Current Finch Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Finch analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Finch analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
50.0 | Buy | 1 | Odds |
Most Finch analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Finch stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Finch Therapeutics, talking to its executives and customers, or listening to Finch conference calls.
Finch Stock Analysis Indicators
Finch Therapeutics Group stock analysis indicators help investors evaluate how Finch Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Finch Therapeutics shares will generate the highest return on investment. By understating and applying Finch Therapeutics stock analysis, traders can identify Finch Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow | 73.8 M | |
Common Stock Shares Outstanding | 1.6 B | |
Total Stockholder Equity | 22.9 M | |
Tax Provision | -3.5 M | |
Property Plant And Equipment Net | 27.2 M | |
Cash And Short Term Investments | 25.1 M | |
Cash | 25.1 M | |
Accounts Payable | 141 K | |
Net Debt | 5 M | |
50 Day M A | 2.6797 | |
Total Current Liabilities | 4.1 M | |
Other Operating Expenses | 84 M | |
Non Current Assets Total | 29.5 M | |
Non Currrent Assets Other | 2.3 M | |
Stock Based Compensation | 1.9 M |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Finch Therapeutics Group. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Finch Therapeutics information on this page should be used as a complementary analysis to other Finch Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Complementary Tools for Finch Stock analysis
When running Finch Therapeutics' price analysis, check to measure Finch Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Finch Therapeutics is operating at the current time. Most of Finch Therapeutics' value examination focuses on studying past and present price action to predict the probability of Finch Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Finch Therapeutics' price. Additionally, you may evaluate how the addition of Finch Therapeutics to your portfolios can decrease your overall portfolio volatility.
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |
Is Finch Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Finch Therapeutics. If investors know Finch will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Finch Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (61.48) | Revenue Per Share 0.067 | Quarterly Revenue Growth (1.00) | Return On Assets (0.19) | Return On Equity (1.26) |
The market value of Finch Therapeutics is measured differently than its book value, which is the value of Finch that is recorded on the company's balance sheet. Investors also form their own opinion of Finch Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Finch Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Finch Therapeutics' market value can be influenced by many factors that don't directly affect Finch Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Finch Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Finch Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Finch Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.